Published in J Cereb Blood Flow Metab on October 17, 2012
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis (2013) 1.62
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 1.41
Prolonged White Matter Inflammation After Cardiopulmonary Bypass and Circulatory Arrest in a Juvenile Porcine Model. Ann Thorac Surg (2015) 1.39
Obesity induced by a high-fat diet is associated with increased immune cell entry into the central nervous system. Brain Behav Immun (2013) 1.15
What causes alopecia areata? Exp Dermatol (2013) 1.14
Interleukin-1β induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. PLoS One (2014) 1.00
Virus infection, antiviral immunity, and autoimmunity. Immunol Rev (2013) 1.00
Differential virulence and pathogenesis of West Nile viruses. Viruses (2013) 0.99
Contrasting pediatric and adult cerebral malaria: the role of the endothelial barrier. Virulence (2013) 0.96
Manifestations of immune tolerance in the human female reproductive tract. Front Immunol (2013) 0.94
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
A detailed method for preparation of a functional and flexible blood-brain barrier model using porcine brain endothelial cells. Brain Res (2013) 0.93
Dealing with Danger in the CNS: The Response of the Immune System to Injury. Neuron (2015) 0.91
The Molecular Constituents of the Blood-Brain Barrier. Trends Neurosci (2015) 0.90
Redox control of microglial function: molecular mechanisms and functional significance. Antioxid Redox Signal (2014) 0.90
Induction of microglia activation after infection with the non-neurotropic A/CA/04/2009 H1N1 influenza virus. PLoS One (2015) 0.88
Immune cascades in human intervertebral disc: the pros and cons. Int J Clin Exp Pathol (2013) 0.88
Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2013) 0.88
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
New advances on glial activation in health and disease. World J Virol (2015) 0.87
HIV-specific CD8+ T cells and HIV eradication. J Clin Invest (2016) 0.85
Banking on iPSC--is it doable and is it worthwhile. Stem Cell Rev (2015) 0.82
Comparison of the global gene expression of choroid plexus and meninges and associated vasculature under control conditions and after pronounced hyperthermia or amphetamine toxicity. BMC Genomics (2013) 0.82
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res (2016) 0.81
The detection of surfactant proteins A, B, C and D in the human brain and their regulation in cerebral infarction, autoimmune conditions and infections of the CNS. PLoS One (2013) 0.81
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell (2014) 0.80
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage. Stroke (2015) 0.79
Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation. PLoS One (2015) 0.78
Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder. J Neurovirol (2013) 0.78
Outer brain barriers in rat and human development. Front Neurosci (2015) 0.77
TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun (2016) 0.77
Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab (2014) 0.76
Targeting the Brain Reservoirs: Toward an HIV Cure. Front Immunol (2016) 0.75
Gene therapy for metachromatic leukodystrophy. J Neurosci Res (2016) 0.75
Cellular Stress Response and Immune Signaling in Retinal Ischemia-Reperfusion Injury. Front Immunol (2016) 0.75
Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology. Toxicol Sci (2015) 0.75
Taenia solium: Development of an Experimental Model of Porcine Neurocysticercosis. PLoS Negl Trop Dis (2015) 0.75
Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg (2014) 0.75
The extracellular matrix protein laminin-10 promotes blood-brain barrier repair after hypoxia and inflammation in vitro. J Neuroinflammation (2016) 0.75
Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget (2016) 0.75
Pregnancy, Labor, and Delivery after Ebola Virus Disease and Implications for Infection Control in Obstetric Services, United States. Emerg Infect Dis (2016) 0.75
The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia. Front Pediatr (2017) 0.75
An immunocompetent mouse model of human glioblastoma. Oncotarget (2017) 0.75
Timeline metastatic progression: in the wake of the « seed and soil » theory. Med Oncol (2017) 0.75
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. Int J Mol Sci (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med (2009) 4.87
Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol (2003) 4.76
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci U S A (2010) 3.68
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature (2009) 3.33
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res (2010) 3.05
Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol (2009) 3.04
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol (2007) 2.85
Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci (2000) 2.75
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci (2011) 2.40
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
The impact of the extracellular matrix on inflammation. Nat Rev Immunol (2010) 2.30
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol (2009) 2.12
Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke (1991) 2.10
Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv (2003) 2.06
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem (2010) 1.85
Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke (2004) 1.81
Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther (2011) 1.79
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol (2009) 1.71
Choroid plexus: biology and pathology. Acta Neuropathol (2009) 1.70
Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta (2010) 1.68
Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res (2002) 1.64
Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer (2004) 1.55
The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.55
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol (2002) 1.54
Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol (2008) 1.52
Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol (2011) 1.47
P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke (1994) 1.44
Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant (2007) 1.38
Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience (2008) 1.37
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol (1999) 1.33
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke (2001) 1.32
Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke (1994) 1.30
Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging (2008) 1.30
Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab (2003) 1.28
The neurovascular unit, matrix proteases, and innate inflammation. Ann N Y Acad Sci (2010) 1.25
Cortical lesions and brain atrophy in MS. J Neurol Sci (2005) 1.24
Blood-brain barrier alterations in ageing and dementia. J Neurol Sci (2009) 1.24
Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res (2006) 1.23
Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med (2011) 1.22
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS (2011) 1.21
Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab (2010) 1.21
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
Interendothelial claudin-5 expression depends on cerebral endothelial cell-matrix adhesion by β(1)-integrins. J Cereb Blood Flow Metab (2011) 1.17
Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des (2008) 1.15
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res (2010) 1.15
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood (2009) 1.15
Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol (2011) 1.13
Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis (2010) 1.13
Ultrastructural and temporal changes of the microvascular basement membrane and astrocyte interface following focal cerebral ischemia. J Neurosci Res (2009) 1.10
Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain (2011) 1.10
Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol (2009) 1.09
The rapid decrease in astrocyte-associated dystroglycan expression by focal cerebral ischemia is protease-dependent. J Cereb Blood Flow Metab (2007) 1.08
Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest (2009) 1.08
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res (2010) 1.07
Tight junctions in cancer metastasis. Front Biosci (Landmark Ed) (2011) 1.07
Systems biology and its application to the understanding of neurological diseases. Ann Neurol (2009) 1.06
Glioma-induced remodeling of the neurovascular unit. Brain Res (2009) 1.04
Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet (2011) 1.03
Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J Neuroimmunol (2008) 1.02
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum (2008) 1.01
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res (2012) 1.01
Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol (2010) 1.01
Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res (2011) 1.00
Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum Mol Genet (2011) 1.00
A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J Cereb Blood Flow Metab (2010) 1.00
The effects of cerebral ischemia on the rat choroid plexus. J Cereb Blood Flow Metab (2006) 0.99
Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J Immunol (2010) 0.99
Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain (2012) 0.98
Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 0.98
Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J Neuroinflammation (2010) 0.97
Evidence for differential changes of junctional complex proteins in murine neurocysticercosis dependent upon CNS vasculature. Brain Res (2007) 0.96
Transplantation of cultured choroid plexus epithelial cells via cerebrospinal fluid shows prominent neuroprotective effects against acute ischemic brain injury in the rat. Neurosci Lett (2009) 0.94
Trafficking of superparamagnetic iron oxide particles (Combidex) from brain to lymph nodes in the rat. Neuropathol Appl Neurobiol (2004) 0.93
Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res (2010) 0.92
Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions. Am J Pathol (1998) 0.92
AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther (2009) 0.92
CNS grafts of rat choroid plexus protect against cerebral ischemia in adult rats. Neuroreport (2004) 0.92
Glia cell number modulates sensitivity to MPTP in mice. Glia (2005) 0.90
Structure and function of the blood-brain barrier. Neurobiol Dis (2009) 7.64
A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature (2005) 6.86
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007) 6.19
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science (2011) 3.52
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Ischemic tolerance and endogenous neuroprotection. Trends Neurosci (2003) 3.44
Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2009) 3.40
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr (2007) 3.40
The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol (2012) 3.07
Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol (2009) 2.87
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol (2007) 2.85
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med (2015) 2.77
Posterior subtemporal transtentorial approach to intraparenchymal lesions of the anteromedial region of the superior cerebellum. J Neurosurg (2005) 2.69
Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol (2007) 2.66
Effect of pregnancy on hemangioblastoma development and progression in von Hippel-Lindau disease. J Neurosurg (2012) 2.65
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A (2009) 2.54
Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest (2002) 2.50
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci (2011) 2.40
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis (2008) 2.26
Neurofibromatosis type 2. Lancet (2009) 2.24
Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol (2005) 2.23
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol (2012) 2.19
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A, and PECAM-1. Blood (2009) 2.10
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2014) 2.07
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab (2008) 2.04
Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol (2002) 2.02
Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol (2003) 1.99
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab (2003) 1.93
Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med (2003) 1.90
Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. J Neurosurg (2011) 1.87
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology (2011) 1.80
VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med (2008) 1.78
Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A (2009) 1.78
Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain (2012) 1.78
Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol (2006) 1.76
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb Blood Flow Metab (2006) 1.75
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum (2008) 1.73
Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA (2007) 1.73
Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci (2007) 1.71
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis (2011) 1.70
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta (2010) 1.68
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev (2008) 1.65
Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery (2005) 1.61
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A (2002) 1.59
Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys (2010) 1.59
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg (2012) 1.59
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. J Exp Med (2003) 1.58
Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2006) 1.58
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med (2004) 1.57
Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke (2009) 1.56
Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg (2006) 1.55
Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci (2003) 1.55
Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol (2005) 1.52
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol (2008) 1.52
How do immune cells support and shape the brain in health, disease, and aging? J Neurosci (2013) 1.51
Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer (2006) 1.50
Direct interstitial infusion of NK1-targeted neurotoxin into the spinal cord: a computational model. Am J Physiol Regul Integr Comp Physiol (2003) 1.50
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates. J Neurosurg (2011) 1.47
A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. J Biol Chem (2002) 1.45
Adaptive mechanisms regulate preferred utilization of ketones in the heart and brain of a hibernating mammal during arousal from torpor. Am J Physiol Regul Integr Comp Physiol (2008) 1.45
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 1.42
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42
Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg (2012) 1.42
Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood (2004) 1.42
Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther (2007) 1.42
Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology (2002) 1.42
Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in von Hippel-Lindau disease. Otol Neurotol (2007) 1.41
Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol (2006) 1.41
Philanthropy funding for neurosurgery research and program development. Neurosurgery (2013) 1.40
Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol (2004) 1.39
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol (2003) 1.39
The history of pituitary surgery for Cushing disease. J Neurosurg (2011) 1.38
SUMOylation participates in induction of ischemic tolerance. J Neurochem (2009) 1.38
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res (2003) 1.38